+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antithrombotic Drugs Market - Global Forecast 2026-2032- Product Image
Antithrombotic Drugs Market - Global Forecast 2026-2032- Product Image
New

Antithrombotic Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 197 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6013888
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Antithrombotic drugs are at the forefront of evolving cardiovascular care, as commercial and clinical strategies increasingly prioritize targeted therapies, safety, and digital integration. This executive summary provides a focused view on market evolution, operational imperatives, and stakeholder priorities in the global antithrombotic drugs market.

Market Snapshot: Antithrombotic Drugs Market Growth, Size, and Dynamics

The Antithrombotic Drugs Market grew from USD 30.04 billion in 2025 to USD 31.72 billion in 2026. It is expected to continue growing at a CAGR of 6.16%, reaching USD 45.68 billion by 2032. Market expansion is supported by the growing global prevalence of cardiovascular and thrombotic disorders, an aging population with multimorbidity, and increased emphasis on safer, patient-centric therapies. Clinical innovation, payer behavior, and supply chain advances collectively underpin sustained adoption and channel diversification.

Scope & Segmentation of the Antithrombotic Drugs Market

This report provides granular analysis across key antithrombotic therapy segments, encompassing clinical pathways and commercial opportunities at a global scale.

  • Drug Classes: Anticoagulants, antiplatelets, and thrombolytics. Anticoagulants include direct oral anticoagulants (direct thrombin inhibitors, factor Xa inhibitors), heparins (low molecular weight and unfractionated), and vitamin K antagonists.
  • Clinical Indications: Focus on atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, and stroke prevention—each imposing unique clinical and commercial challenges.
  • Routes of Administration: Oral formulations favor chronic, outpatient adherence; parenteral options are preferred in acute and peri-procedural settings.
  • End-User Channels: Hospital procurement cycles, home care models, and retail pharmacy channels each shape uptake and reimbursement profiles.
  • Regional Focus: Americas, EMEA (Europe, Middle East & Africa), and Asia-Pacific. Markets differ in regulatory systems, payer dynamics, coverage access, and manufacturing landscapes.
  • Technology Levers: Emerging digital adherence platforms, remote patient monitoring, and point-of-care diagnostic innovations support clinical management and patient engagement.

Key Takeaways: Strategic Trends and Stakeholder Priorities

  • Direct oral anticoagulants continue to shift standard-of-care decisions, with ongoing innovation in dosing precision and reversal agents.
  • Payers and formulary committees are emphasizing real-world evidence and pragmatic trial data, moving beyond randomized trial hierarchies.
  • Supply chain resilience and regional manufacturing capacity have become key competitive differentiators after recent global disruptions.
  • Strategic partnerships—among originators, generic manufacturers, and contract partners—enable supply continuity and cost-effective production.
  • Digital patient support and data-driven adherence solutions are enhancing product differentiation and stakeholder value.
  • Lifecycle management strategies, including indication expansions and label extensions, are supporting sustained market leadership.

Tariff Impact: Operational and Supply Chain Implications (United States Focus)

Anticipated United States tariff measures in 2025 are projected to increase import costs for active ingredients and finished injectables, challenging manufacturers reliant on global supply chains. Firms are responding by evaluating nearshoring, regional production, and multi-source procurement. Tariffs may also delay clinical development, regulatory submissions, and commercial launches due to logistics bottlenecks. Hospitals and payers may shift toward locally manufactured antithrombotics or those with simplified supply chains to mitigate disruption. Preparedness—through contingency inventory, sourcing diversification, and regulatory engagement—remains essential for continuity.

Methodology & Data Sources

This analysis draws on expert interviews with clinicians, industry leaders, and hospital pharmacologists, comprehensive review of clinical and regulatory data, segmentation mapping, and supply chain scenario analysis. Data triangulation and validation were performed to ensure decision-grade insights and operational relevance.

Why This Report Matters

  • Delivers actionable insights for commercial, medical, and policy leaders to assess antithrombotic drug opportunities and competitive positioning.
  • Offers clarity on emerging technology, segmentation, and regional factors influencing adoption, regulatory approval, and reimbursement.
  • Guides operational planning around supply chain risks, tariff exposure, and digital health integration for market success.

Conclusion

The antithrombotic drugs market is shaped by advances in therapy, regulatory and payer demands, and supply chain adaptation. Senior stakeholders are encouraged to focus on agility, evidence alignment, and regional diversity to convert therapeutic innovation into commercial advantage.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Antithrombotic Drugs Market, by Drug Class
8.1. Anticoagulants
8.1.1. Direct Oral Anticoagulants
8.1.2. Heparins
8.1.2.1. Low Molecular Weight Heparin
8.1.2.2. Unfractionated Heparin
8.1.3. Vitamin K Antagonists
8.2. Antiplatelets
8.3. Thrombolytics
9. Antithrombotic Drugs Market, by Indication
9.1. Atrial Fibrillation
9.2. Deep Vein Thrombosis
9.3. Myocardial Infarction
9.4. Pulmonary Embolism
9.5. Stroke Prevention
10. Antithrombotic Drugs Market, by Route Of Administration
10.1. Oral
10.2. Parenteral
11. Antithrombotic Drugs Market, by End User
11.1. Home Care
11.2. Hospital
11.3. Retail Pharmacy
12. Antithrombotic Drugs Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Antithrombotic Drugs Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Antithrombotic Drugs Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Antithrombotic Drugs Market
16. China Antithrombotic Drugs Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Amgen
17.6. Aspen Holdings
17.7. AstraZeneca plc
17.8. Bayer AG
17.9. Boehringer Ingelheim International GmbH
17.10. Bristol-Myers Squibb Company
17.11. Daiichi Sankyo Company, Limited
17.12. Eli Lilly and Company
17.13. F. Hoffmann-La Roche Ltd.
17.14. Fresenius Kabi AG
17.15. Gilead Sciences
17.16. GlaxoSmithKline plc
17.17. Hikma Pharmaceuticals PLC
17.18. Johnson & Johnson Services, Inc.
17.19. Merck & Co., Inc.
17.20. Novartis AG
17.21. Otsuka Pharmaceutical Co., Ltd.
17.22. Pfizer Inc.
17.23. Sanofi S.A.
17.24. Takeda Pharmaceutical Company Limited
17.25. Teva Pharmaceutical Industries Ltd.
17.26. Viatris Inc
List of Figures
FIGURE 1. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTITHROMBOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 93. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 94. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 95. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 96. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 107. AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 108. AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 109. AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 110. AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. ASEAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASEAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 122. ASEAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 123. ASEAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 124. ASEAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 125. ASEAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. ASEAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. GCC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GCC ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 129. GCC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 130. GCC ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 131. GCC ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 132. GCC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. GCC ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. BRICS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. BRICS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 143. BRICS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 144. BRICS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 145. BRICS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. BRICS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 147. BRICS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. G7 ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. G7 ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 150. G7 ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 151. G7 ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 152. G7 ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 153. G7 ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. G7 ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. NATO ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. NATO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. NATO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 158. NATO ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 159. NATO ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 160. NATO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. NATO ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 167. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 168. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 171. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
TABLE 173. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2032 (USD MILLION)
TABLE 174. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 175. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Antithrombotic Drugs market report include:
  • Amgen
  • Aspen Holdings
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc

Table Information

Report AttributeDetails
No. of Pages197
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 31.72 Billion
Forecasted Market Value ( USD ) by 2032 $ 45.68 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Antithrombotic Drugs Market - Global Strategic Business Report - Product Image

Antithrombotic Drugs Market - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Direct Thrombin Inhibitors Market - Global Forecast 2025-2030 - Product Image

Direct Thrombin Inhibitors Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Factor Xa Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Factor Xa Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Factor XI Inhibitors - Pipeline Insight, 2025 - Product Image

Factor XI Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Argatroban Market - Global Forecast 2026-2032 - Product Image

Argatroban Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From

About the Antithrombotics Market

Antithrombotics are drugs used to prevent the formation of blood clots, which can lead to cardiovascular diseases such as stroke and heart attack. These drugs work by inhibiting the activity of clotting factors in the blood, thus preventing the formation of clots. Common antithrombotics include aspirin, clopidogrel, warfarin, and heparin. Aspirin is the most widely used antithrombotic, and is often prescribed to reduce the risk of stroke and heart attack. Clopidogrel is used to prevent blood clots in patients with coronary artery disease, while warfarin is used to prevent and treat blood clots in patients with atrial fibrillation. Heparin is used to prevent and treat deep vein thrombosis and pulmonary embolism. The antithrombotics market is highly competitive, with many large pharmaceutical companies offering a range of products. Some of the major players in the market include Bayer, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. These companies are continuously developing new products to meet the needs of patients and healthcare providers. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.